Eledon Pharma Analyst Ratings
Eledon Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/24/2023 | 900% | HC Wainwright & Co. | $25 → $13 | Maintains | Buy |
| 09/27/2023 | 669.23% | Noble Capital Markets | → $10 | Initiates Coverage On | → Outperform |
| 08/22/2023 | 592.31% | Cantor Fitzgerald | → $9 | Reiterates | Overweight → Overweight |
| 05/26/2023 | 1823.08% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 06/01/2022 | 1900% | SVB Leerink | $33 → $26 | Maintains | Outperform |
| 11/24/2021 | 1823.08% | HC Wainwright & Co. | $35 → $25 | Maintains | Buy |
| 04/27/2021 | 2438.46% | SVB Leerink | $34 → $33 | Maintains | Outperform |
| 03/23/2021 | 1823.08% | Cantor Fitzgerald | → $25 | Initiates Coverage On | → Overweight |
| 02/08/2021 | 2515.38% | SVB Leerink | → $34 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月24日 | 900% | HC Wainwright公司 | $25→$13 | 維護 | 買 |
| 09/27/2023 | 669.23% | 來寶資本市場 | →$10 | 開始承保 | →跑贏大盤 |
| 2023年08月22日 | 592.31% | 康託·菲茨傑拉德 | →$9 | 重申 | 超重→超重 |
| 2023年05月26日 | 1823.08% | HC Wainwright公司 | →$25 | 重申 | 購買→購買 |
| 06/01/2022 | 1900% | SVB Leerink | $33→$26 | 維護 | 跑贏大盤 |
| 2021年11月24日 | 1823.08% | HC Wainwright公司 | $35→$25 | 維護 | 買 |
| 04/27/2021 | 2438.46% | SVB Leerink | $34→$33 | 維護 | 跑贏大盤 |
| 03/23/2021 | 1823.08% | 康託·菲茨傑拉德 | →$25 | 開始承保 | →超重 |
| 02/08/2021 | 2515.38% | SVB Leerink | →$34 | 開始承保 | →跑贏大盤 |
What is the target price for Eledon Pharma (ELDN)?
Eledon Pharma(ELDN)的目標價是多少？
The latest price target for Eledon Pharma (NASDAQ: ELDN) was reported by HC Wainwright & Co. on October 24, 2023. The analyst firm set a price target for $13.00 expecting ELDN to rise to within 12 months (a possible 900.00% upside). 4 analyst firms have reported ratings in the last year.
納斯達克(Eledon Pharma)的最新目標價是由HC Wainwright&Co.於2023年10月24日報道的。這家分析公司將目標價定為13美元，預計ELDN將在12個月內上漲至(可能上漲900.00%)。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Eledon Pharma (ELDN)?
Eledon Pharma(ELDN)的最新分析師評級是多少？
The latest analyst rating for Eledon Pharma (NASDAQ: ELDN) was provided by HC Wainwright & Co., and Eledon Pharma maintained their buy rating.
納斯達克(Sequoia Capital：ELDN)的最新分析師評級由HC Wainwright&Co.提供，Eledon Pharma維持買入評級。
When is the next analyst rating going to be posted or updated for Eledon Pharma (ELDN)?
Eledon Pharma(ELDN)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eledon Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eledon Pharma was filed on October 24, 2023 so you should expect the next rating to be made available sometime around October 24, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Eledon Pharma的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。對Eledon Pharma的最後一次評級是在2023年10月24日提交的，所以你應該預計下一次評級將在2024年10月24日左右的某個時候公佈。
Is the Analyst Rating Eledon Pharma (ELDN) correct?
分析師對Eledon Pharma(ELDN)的評級正確嗎？
While ratings are subjective and will change, the latest Eledon Pharma (ELDN) rating was a maintained with a price target of $25.00 to $13.00. The current price Eledon Pharma (ELDN) is trading at is $1.30, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Eledon Pharma(ELDN)評級維持不變，目標價在25.00美元至13.00美元之間。目前Eledon Pharma的交易價格為1.30美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。